Evidence mapPaperPMID 31258982Full record

ArticleAMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science2019

Feature Selection in Predictive Modeling: A Systematic Study on Drug Response Heterogeneity for Type II Diabetic Patients.

Jingyuan Chou, James Flory, Fei Wang

Abstract read
In one paragraph

Article in AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jingyuan ChouDepartment of Healthcare Policy and Research. Weill Cornell Medicine.
James FloryDepartment of Healthcare Policy and Research. Weill Cornell Medicine.
Fei WangDepartment of Healthcare Policy and Research. Weill Cornell Medicine.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the rapid development of computer hardware and software technologies, more and more electronic health data from insurance claims, clinical trials and hospitals are becoming readily available. These data provide a rich resource for developing various healthcare analytics algorithms, among which predictive modeling is of key importance in many real health problems. One important issue for data-driven predictive modeling is high dimensionality, and feature selection is one effective strategy to reduce the number of independent variables and control the confounding factors. However, most of the existing studies just pick one feature selection approach without comprehensive investigations. In this paper, we investigate the issue of drug response heterogeneity for type II diabetes mellitus (T2DM) patients using a large scale clinical trial data. Our goal is to find out the important factors that may lead to the response heterogeneity for three popular T2DM drugs, Metformin, Rosiglitazone and Glimepiride. We implemented 8 different feature selection approaches and compared their performances with various measures including prediction error and the consistency of the identified important factors. Finally, we ensemble all factor lists picked by different algorithms and obtain a final set of factors that contribute to the drug response heterogeneities and verified them through existing literature.

Identifiers

PMID31258982
PMCPMC6568100

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.